About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings

By: MarketBeat

A dose of injectable Ozempic from Danish company Novo Nordisk

Novo Nordisk (NYSE: NVO) is the world’s second-largest pharmaceutical company, with a market capitalization of $538 billion. The Danish firm’s shares have performed well so far in 2024, returning 23%, outperforming its sector. The iShares Global Healthcare ETF (NYSEARCA: IXJ) has returned 11%.

The firm's standout performance largely stems from its successful weight-loss and type 2 diabetes drugs, Ozempic and Wegovy. Let's delve into the firm's segments, highlight key points from the earnings release, explore the market reaction to a major competitor's earnings, and outline critical factors to monitor moving forward.

Novo Nordisk: Addressing the Massive Obesity and Diabetes Markets

Novo Nordisk divides its operations into two segments: Diabetes and Obesity and Rare Disease. Diabetes and Obesity are by far the most important, comprising over 90% of total sales in 2023.

The firm's weight loss and diabetes drugs address massive markets. As of 2022, over 1 billion people worldwide, or around one-eighth of the world’s population, lived with obesity. In 2021, 529 million people lived with diabetes, and 96% of those had type 2 diabetes, equal to 6.4% of the world's population at that time.

Shares Fall on Underwhelming Ozempic and Wegovy Growth

Novo Nordisk's shares fell over 8% after its earnings report. This was due to weight loss and diabetes drug sales missing expectations. Sales growth for Ozempic and Wegovy remained strong, rising 30% and 53%, respectively, in constant currency terms, although Wegovy's sales fell 14% short of analysts' expectations.

Wegovy is especially important because it treats obesity, the larger target market, while Ozempic treats type 2 diabetes. The firm’s CEO, Lars Jørgensen, attributed the sales miss to a decline in price due to a “one-off true-up for rebates given last year."

The firm agreed to pay rebates to insurance companies after they purchased the drugs in 2023, which it had to make good on in the quarter.

Novo Nordisk missed on earnings per share (EPS) substantially, coming in at 4.49 Danish kroner, equivalent to 66 cents USD. This was an earnings surprise of -9% and an increase of 4% from the previous year.

Net sales came in 500 million Danish kroner ($73,120,800 USD) below expectations, for a surprise of -0.07%. This represented an increase of 25% from the previous year. The company also saw its operating margin contract greatly, falling nearly 600 basis points from Q2 2023.

The company is expecting its operating margin to decline through the rest of the year. It raised revenue growth guidance to a midpoint of 25% but lowered operating profit growth to a midpoint of 24%.

Eli Lilly’s Results Ease Concerns, Shooting Shares Back Up

Curiously, the next day, shares recovered almost all the ground they lost, up 7.5%. The financial results of Eli Lilly (NYSE: LLY), released the day after Novo Nordisk's, contributed to this.

Lilly beat estimates on growth for its drugs Zepbound and Mounjaro by a wide margin. Zepbound, the rival to Wegovy, was the most important sign. It beat sales estimates by 33%. This eased concerns that the overall weight loss drug market growth is decelerating, helping Novo’s shares recover.

We can see the strong relationship between these two firms' results, as on the day of Novo’s negative earnings, Eli Lilly also fell over 2%.

NVO Needs Investments in Increased Supply to Pay Off

Seeing Novo Nordisk manage its supply constraints will be key to the firm's future success. Novo has had trouble producing enough of Ozempic and Wegovy’s active ingredient, liraglutide.

On Aug. 6, Novo showed it is making strides in increasing supply, with only the smallest of its four Wegovy doses listed as having "limited availability" in the FDA database.

However, this low dose is particularly important because patients start their treatment at this level and work their way up. Constrained supply here significantly lowers the amount of new patient growth that Wegovy can garner.

Increasing the supply of semaglutide is vital not only for the growth of Wegovy and Ozempic but also for the oral version of Wegovy, which is in Phase III FDA trials. Taking oral treatments as a once-daily pill could help introduce the drugs to a new market of people uncomfortable with needles.

However, since the body tends to absorb oral drugs less efficiently, the oral version needs more semaglutide. Novo’s supply of semaglutide should improve, considering the billions of dollars the company invested in manufacturing capacity in 2023 and 2024.

More News

View More
After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
Via MarketBeat
Topics Government
Tickers GOOGL META ORCL
Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Via MarketBeat
Topics ETFs World Trade
Tickers FTXR JBHT RXO SAIA
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
Via MarketBeat
Tickers QURE
Robinhood Up 12%—Could Prediction Markets Be Its Secret Weapon?
Via MarketBeat
Topics Earnings
Tickers DKNG FLUT HOOD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.